SomnoMed Limited
Climate Impact & Sustainability Data (2023, 2024)
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:8.8478 tCO2e/year
Scope 1 Emissions:0.0000 tCO2e/year
Scope 2 Emissions:0.0000 tCO2e/year
Scope 3 Emissions:8.8478 tCO2e/year
ESG Focus Areas
- Climate Change
Climate Goals & Targets
Long-term Goals:
- Achieve net zero emissions by 2050
Medium-term Goals:
- Reduce emissions by switching away from diesel powered vehicles by 2030
- Offset any remaining carbon emissions by 2030
Short-term Goals:
- Reduce paper use by 20% in 2025
Environmental Challenges
- Reducing emissions to net-zero by 2050
Mitigation Strategies
- Reduce use of printed marketing materials
- Business mileage emission reduction by switching to hybrid/electric vehicles
- Carbon offsetting for remaining emissions
- Using lowest impact transport methods for receiving and delivering goods
Supply Chain Management
Responsible Procurement
- Only use delivery companies who have a CRP in place
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: PPN 06/21, GHC Reporting Protocol
Reporting Period: 2024
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Challenging environment impacting revenue growth.
- Slow turnaround times impacting Q4 revenue in Europe.
- Ongoing absence of reimbursement and tightening economic environment in Asia Pacific.
- US FDA requested further information for Rest Assure®.
Mitigation Strategies
- Significant organisational transformation resulting in annualised savings of $5 million.
- Investments in expanding manufacturing capacity and optimising efficiency.
- Focus on cost reduction and productivity optimisation in North America.
- Exploring reimbursement strategy with PDAC for SomnoDent® AvantTM in North America.
- Focus on customer outreach and productivity optimisation in Asia Pacific.
- Expected response to FDA by early September 2024 for Rest Assure®; global beta market entry planned for 2025.